Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-019202

CHIEF SCIENTIFIC OFFICER sold 12,000 shares at $22.89 ($274,736)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-07-01 Sale 10b5-1 −12,000 $22.89 $274,736 1,105,035 I: show line 1 in the form
Open-market sales · 12,000 sh · avg $22.89 · $274,736
Loading xslF345X05/form4-07032024_080732.xml…